Skip to main content
. 2017 Oct 11;8(61):103207–103222. doi: 10.18632/oncotarget.21732

Figure 1. PI3’K inhibition counteracts PLX-4720 resistance in a double mutant thyroid cancer mouse model.

Figure 1

(A) Schematic timeline depiction of in vivo Experiment. Tumor burden in single mutant BrafCA/+; ThyroglobulinCreERT2 mice (B) and double mutant BrafCA/+; Pik3caLat/+; ThyroglobulinCreERT2 mice (C) in percentage of the tumor burden at the beginning of the drug treatment. Crosses represent events of mice reaching end-point criteria. (D) Representative pictures from ultrasound imaging of double mutant mice after 70 days of treatment used for assessment of the tumor burden. Thyroid outlines are shown by blue lines.